Abstracts tagged "Lupus"

Abstract Number: 14 • 2015 ACR/ARHP Annual Meeting
The SLE Susceptibility Gene Macrophage Migration Inhibitory Factor Serves As an Upstream Regulator of NLRP3 (NOD-like receptor family pyrin domain containing 3) Expression and Subsequent IL-1beta Production in Human Monocytes in Response to Lupus U1-snRNP Immune Complex
Min Sun Shin¹, Youna Kang¹, Elizabeth Wahl¹, Lin Leng¹, Richard Bucala¹ and Insoo Kang², ¹Yale University School of Medicine, New Haven, CT, ²Rheumatology Section, Yale University School of Medicine, New Haven, CT
Background/Purpose: The pathologic hallmarks of systemic lupus erythematosus (SLE or lupus) are altered immune responses to nuclear autoantigens with autoantibody production and subsequent tissue injury.…
Abstract Number: 762 • 2015 ACR/ARHP Annual Meeting
The Interferon Signature Correlates with Longitudinal Disease Severity in Systemic Lupus Erythematosus, but Adds Little to Conventional Prognostic Indicators
Arundip Asaduzzaman¹, Babak Noamani², Denisse Bonilla³, Dafna Gladman⁴, Murray Urowitz^5,6, Paul R. Fortin⁷, Carolina Landolt-Marticorena⁸ and Joan E. Wither⁹, ¹Rheumatology, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ²Genetics and developmental biology, University Health Network, Toronto, ON, Canada, ³University Health Network, Toronto, ON, Canada, ⁴Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁵University of Toronto, Toronto, ON, Canada, ⁶Rheumatology, U of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁷Université Laval, CHU de Québec, Québec, QC, Canada, ⁸1E420/Div of Rheumatology, University Health Network, Toronto, ON, Canada, ⁹Rheumatology, University Health Network, Toronto, ON, Canada
Background/Purpose: Type I interferon (IFN) is thought to play an important part in the pathophysiology of systemic lupus erythematosus (SLE), and cross-sectional data suggests an…
Abstract Number: 1106 • 2015 ACR/ARHP Annual Meeting
Efficacy of Abbv-105, a Selective and Irreversible Inhibitor of Bruton’s Tyrosine Kinase (BTK), in Multiple Models of Inflammation
Christian Goess¹, Candace Graff², Ting Ting Zhang², Gregory Preston², Richard McCarthy¹, Matthew Perham¹, Jacqueline Loud¹, Christopher M. Harris¹, Sara Murdock¹, Erik Sampson³, Michael Hoemann⁴, Michael Friedman⁴, Robert Talanian³, Jeremy Edmunds⁴ and Andrew Long¹, ¹Immunology Pharmacology, AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA, ²DMPK, AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA, ³AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA, ⁴Chemistry, AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA
Background/Purpose: Bruton’s Tyrosine Kinase (BTK) is a non-receptor tyrosine kinase required for intracellular signaling pathways downstream of several key immunoreceptors, including the B cell receptor,…
Abstract Number: 1825 • 2015 ACR/ARHP Annual Meeting
Osteoprotegerin Is Associated with Lupus and with Coronary Artery Calcification
Indu Poornima¹, Kelly J. Shields², Susan Manzi³, Rosalind Ramsey-Goldman⁴, Carrie Richardson⁵, Lewis Kuller⁶, George Kondos⁷, James Carr⁵, Craig Langman⁵, Heather Price⁵, Daniel Edmundowicz⁸ and Rachel Mackey⁹, ¹Division of Cardiology, Allegheny Health Network, Pittsburgh, PA, ²Rheumatology, Allegheny Singer Research Institute, Pittsburgh, PA, ³Rheumatology, Allegheny Health Network, Pittsburgh, PA, ⁴Northwestern University Feinberg School of Medicine, Chicago, IL, ⁵Northwestern University, Evanston, IL, ⁶Epidemiology, University of Pittsburgh, Pittsburgh, PA, ⁷University of Illinois in Chicago, Chicago, IL, ⁸Cardiology, Temple University School of Medicine, Philadelphia, PA, ⁹Department of Epidemiology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: In the general population, we and others have reported that higher osteoprotegerin (OPG), a protein involved in bone remodeling, is associated with higher levels…
Abstract Number: 2926 • 2015 ACR/ARHP Annual Meeting
Cytochrome P450 Polymorphisms on Blood Hydroxychloroquine Levels in Patients with Systemic Lupus Erythematosus
Ji Yeon Lee¹, Min Kyung Chung², Ji Hun Kim², Jung Hee Koh³, Seung Min Jung⁴, Jennifer Lee², Seung-Ki Kwok⁵, Ji Hyeon Ju⁶, Kyung-Su Park⁷ and Sung-Hwan Park², ¹Division of Rheumatology, Department of Internal Medicine, School of Medicine, Catholic University of Korea, Seoul St. Mary’s Hospital, Seoul, South Korea, ²Division of Rheumatology, Department of Internal Medicine, College of Medicine, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, South Korea, ³Division of Rheumatology, Department of Internal Medicine, School of Medicine, The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, South Korea, ⁴Division of Rheumatology, Department of Internal Medicine, school of medicine, The catholic university of Korea, Seoul, South Korea, ⁵[email protected], Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea, ⁶Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea, ⁷Division of Rheumatology, Internal Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, South Korea
Background/Purpose: Hydroxychloroquine (HCQ) is a safe and effective treatment for systemic lupus erythematosus (SLE), and its blood concentration is known to be closely related to…
Abstract Number: 24 • 2015 ACR/ARHP Annual Meeting
Investigating the Role of Vitamin D in the Transition to Systemic Lupus Erythematosus in Individuals at Risk for the Disease
Kendra A. Young¹, Melissa E. Munroe², Joel M. Guthridge², Diane L. Kamen³, Timothy B. Niewold⁴, Gary S. Gilkeson⁵, Michael H. Weisman⁶, Mariko L. Ishimori⁶, Daniel J Wallace⁷, David R. Karp⁸, John B. Harley⁹, Judith A. James¹⁰ and Jill M. Norris¹¹, ¹Epidemiology, University of Colorado Denver, Aurora, CO, ²Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Medicine, Medical University of South Carolina, Charleston, SC, ⁴Division of Rheumatology and Department of Immunology, Mayo Clinic, Rochester, MN, ⁵Department of Rheumatology, Medical University of South Carolina, Charleston, SC, ⁶Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁷Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁸Internal Medicine - Rheumatic Diseases, University of Texas Southwestern Medical Center, Dallas, TX, ⁹Center for Autoimmune Genomics and Etiology (CAGE), Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹⁰Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ¹¹University of Colorado Denver, Aurora, CO
Background/Purpose: Lower vitamin D levels are associated with increased disease activity in systemic lupus erythematosus (SLE) and individuals with SLE have increased prevalence of vitamin…
Abstract Number: 768 • 2015 ACR/ARHP Annual Meeting
The Lupus Foundation of America Rapid Evaluation of Activity in Lupus (LFA-REAL) Instrument Correlates Between Trained Clinical Investigators and Clinicians
Anca Askanase¹, Teja Kapoor², Cynthia Aranow³, Karen H. Costenbader⁴, Jennifer Grossman⁵, Diane L. Kamen⁶, S. Sam Lim⁷, Mimi Kim⁸, Paola Daly^9,10, Leslie M. Hanrahan¹¹ and Joan T. Merrill¹², ¹NYU School of Medicine, New York, NY, ²Columbia University, New York, NY, ³Feinstein Institute for Medical Research, Mahasset, NY, ⁴Rheumatology, Immunology & Allergy, Brigham & Women's Hospital, Boston, MA, ⁵Rheumatology, UCLA, LA, CA, ⁶Medicine, Medical University of South Carolina, Charleston, SC, ⁷Emory University School of Medicine, Atlanta, GA, ⁸Biostatistics and Research Design Resource, Albert Einstein Coll Med, Bronx, NY, ⁹Lupus Foundation of America, Washington DC, DC, ¹⁰Lupus Foundation of America, Washington, DC, ¹¹Lupus Fnd of America, Washington, DC, ¹²Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Current SLE disease activity measures, such as SLEDAI and BILAG, can be challenging to score and interpret, making them impractical for use in…
Abstract Number: 1115 • 2015 ACR/ARHP Annual Meeting
B Cell-Intrinsic Interferon Gamma Signals Promote the Development of Systemic Lupus Erythematosus By Enhancing the Formation of Spontaneous Autoimmune Germinal Centers
Shaun Jackson, Nicole Scharping, Holly Jacobs, Tanvi Arkatkar, Socheath Khim and David Rawlings, Seattle Children's Research Institute, Seattle, WA
Background/Purpose: Type 1 interferon (IFN) is strongly implicated in lupus pathogenesis, and SLE patients frequently express a “type 1 IFN gene signature”. The type 2…
Abstract Number: 1843 • 2015 ACR/ARHP Annual Meeting
Bloodstream Infections in Systemic Lupus Erythematosus Patients Are Associated with Severe Lupus Flares
José Jiram Torres Ruiz¹, Ana Barrera-Vargas², Rigoberto Ortíz-Hernández², Jorge Alcocer-Varela² and Diana Gómez-Martín², ¹Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico, Mexico, ²Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose: Infections are an important cause of mortality and morbidity in systemic lupus erythematosus (SLE) patients. Bloodstream infections (BI), which are especially severe and relatively…
Abstract Number: 2946 • 2015 ACR/ARHP Annual Meeting
Mortality Among SLE Patients in the National Data Bank for Rheumatic Diseases
Kaleb Michaud¹, Sofia Pedro² and Patricia P. Katz³, ¹Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ²National Data Bank for Rheumatic Diseases, Wichita, KS, ³Medicine/Rheumatology, University of California San Francisco, San Francisco, CA
Background/Purpose: To investigate risk of mortality among SLE patients cohort in the NDB.Methods: Systemic lupus erythematous (SLE) and non-inflammatory rheumatic disease (NIRD) patients were studied…
Abstract Number: 2644 • 2014 ACR/ARHP Annual Meeting
Carotid Intima-Media Thickness and Plaque in Mexican Mestizos with Systemic Lupus Erythematosus: A Case-Control Study
Iris J. Colunga-Pedraza¹, Dionicio A. Galarza-Delgado¹, Alberto Cardenas-de La Garza¹, Ana L. Sanchez-Nuñez¹, Samantha L. Segarra-Linares¹, Rocío A. Carrillo-Palacios¹, David Vega-Morales¹, Fernando Góngora-Rivera² and Mario Alberto Garza-Elizondo¹, ¹Rheumatology, Hospital Universitario UANL, Monterrey, Mexico, ²Neurology., Hospital Universitario UANL, Monterrey, Mexico
Background/Purpose Systemic lupus erythematosus (SLE) patients are at risk of premature cardiovascular disease (CVD). The specific reason of this situation is still debatable. Subclinical atherosclerosis…
Abstract Number: 1297 • 2014 ACR/ARHP Annual Meeting
Safety and Efficacy of Rituximab in Pediatric Lupus and Other Rheumatic Diseases
Ajay Tambralli¹, Timothy Beukelman², Randy Q. Cron² and Matthew L. Stoll², ¹Medicine, University of Rochester, Rochester, NY, ²Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Rituximab (RTX) is a chimeric monoclonal antibody that specifically targets CD20 positive B cells and is used successfully for a variety of pediatric rheumatologic…
Abstract Number: 674 • 2014 ACR/ARHP Annual Meeting
A Novel Strategy to Identify and Evaluate Approved Drugs and Treatments for Repositioning As Therapies for Systemic Lupus Erythematosus (SLE)
Peter E. Lipsky, Matthew Ryals, Jacob Smearman, Victoria Soler and Amrie Grammer, AMPEL BioSolutions, Charlottesville, VA
Background/Purpose: Development of new SLE treatments has been slow with only one new treatment approved in the past half century. One way to increase the…
Abstract Number: 2643 • 2014 ACR/ARHP Annual Meeting
Angiogenic and Antiangiogenic Factors in Patients with Systemic Lupus Erythematosus
Guilherme Ramires de Jesus¹, Camila Souto Oliveira², Flavia Cunha dos Santos³, Nilson Ramires de Jesus³, Luis Cristovao Porto⁴, Roger A. Levy⁵ and Evandro Mendes Klumb⁶, ¹Department of Obstetrics, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ²Rheumatology, Hospital Universitario Pedro Ernesto, Rio de Janeiro, Brazil, ³Obstetrics, Hospital Universitario Pedro Ernesto, Rio de Janeiro, Brazil, ⁴Immunology, Hospital Universitario Pedro Ernesto, Rio de Janeiro, Brazil, ⁵Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ⁶Rheumatology, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil
Background/Purpose SLE mainly affects young women and pregnancy in these patients has significant morbidity and mortality. Clinical and laboratory findings in lupus nephritis are similar…
Abstract Number: 1213 • 2014 ACR/ARHP Annual Meeting
Absence of Hormone Responsive Estrogen Receptor Alpha Reduces the Activation of Plasmacytoid Dendritic Cells in Lupus Prone Mice
Jennifer L. Scott¹, Melissa A. Cunningham², Osama S. Naga³, Jackie G. Eudaly³, Jena R. Wirth⁴ and Gary S. Gilkeson⁵, ¹Microbiology and Immunology, Medical University of South Carolina, Charleston, SC, ²Rheumatology and Immunology, Medical University of South Carolina, Charleston, SC, ³Medicine/Rheumatology, Medical University of South Carolina, Charleston, SC, ⁴Med/Rheumatology, MUSC, Charleston, SC, ⁵Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, SC
Background/Purpose Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease that affects women at a 9 to 1 ratio compared to men. To further understand…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].